Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Jin Medical InternationalZJYL +4.98%64 WACC % is 24.01% as of Jul. 15, 2026, which is 163% above its 10-year median of 9.13. GuruFocus rates ZJYL with a GF Score™ of 64/100 and a GF Value™ of $14.58 (Significantly Undervalued). The stock has 7 warning signs investors should review. Among 865 Medical Devices & Instruments companies, Jin Medical International ranks worse than 98.38% on this metric.
As of today (2026-07-15), Jin Medical International's weighted average cost of capital is 24.01%%. Jin Medical International's ROIC % is 2.40% (calculated using TTM income statement data).
Jin Medical International earns returns that do not match up to its cost of capital. It will destroy value as it grows.
For a comprehensive WACC calculation, please access the WACC Calculator.
Jin Medical International (NAS:ZJYL) WACC % Explanation
Because it costs money to raise capital. A firm that generates higher ROIC % than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.
As of today, Jin Medical International's weighted average cost of capital is 24.01%%. Jin Medical International's ROIC % is 2.40% (calculated using TTM income statement data).
Jin Medical International earns returns that do not match up to its cost of capital. It will destroy value as it grows.
Be Aware
1. GuruFocus uses book value of debt (D) to do the calculation. It is simplified by adding latest one-year semi-annual average Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation together.
For companies that report quarterly, GuruFocus combines all of the most recent year's quarterly debt data from the beginning of the year to the year-end and calculates the average.
For companies that report semi-annually, GuruFocus combines all of the most recent year's semi-annual debt data from the start of the year to the year-end and calculates the average.
For companies that report annually, GuruFocus combines the beginning and ending annual debt data from the most recent year and then calculates the average.
2. The WACC formula discussed above does not include Preferred Stock. Please adjust if preferred stock is considered.
3. (Expected Return of the Market - Risk-Free Rate of Return) is also called market premium. GuruFocus requires market premium to be 6%.
4. GuruFocus uses the latest TTM Interest Expense divided by the latest one-year semi-annual average debt to get the simplified cost of debt.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Jin Medical International's WACC %, along with its competitors' market caps and WACC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jin Medical International WACC % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Jin Medical International's WACC % distribution charts can be found below:
* The bar in red indicates where Jin Medical International's WACC % falls into.
The weighted average cost of capital (WACC) is the rate that a company is expected to pay on average to all its security holders to finance its assets. The WACC is commonly referred to as the firm's cost of capital. Generally speaking, a company's assets are financed by debt and equity. WACC is the average of the costs of these sources of financing, each of which is weighted by its respective use in the given situation. By taking a weighted average, we can see how much interest the company has to pay for every dollar it finances.
WACC
=
E
/
(E + D)
*
Cost of Equity
+
D
/
(E + D)
*
Cost of Debt
*
(1 - Tax Rate)
1. Weights:
Generally speaking, a company's assets are financed by debt and equity. We need to calculate the weight of equity and the weight of debt.
The market value of equity (E) is also called "Market Cap". As of today, Jin Medical International's market capitalization (E) is $15.342 Mil.
The market value of debt is typically difficult to calculate, therefore, GuruFocus uses book value of debt (D) to do the calculation. It is simplified by adding the latest one-year semi-annual average Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation together. As of Sep. 2025, Jin Medical International's latest one-year semi-annual average Book Value of Debt (D) is $15.4767 Mil.
a) weight of equity = E / (E + D) = 15.342 / (15.342 + 15.4767) = 0.4978
b) weight of debt = D / (E + D) = 15.4767 / (15.342 + 15.4767) = 0.5022
2. Cost of Equity:
GuruFocus uses Capital Asset Pricing Model (CAPM) to calculate the required rate of return. The formula is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)
a) GuruFocus uses 10-Year Treasury Constant Maturity Rate as the risk-free rate. It is updated daily. The current risk-free rate is 4.616%. Please go to Economic Indicators page for more information. Please note that we use the 10-Year Treasury Constant Maturity Rate of the country/region where the company is headquartered. If the data for that country/region is not available, then we will use the 10-Year Treasury Constant Maturity Rate of the United States as default.
b) Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. Jin Medical International's beta is 7.2706.
c) (Expected Return of the Market - Risk-Free Rate of Return) is also called market premium. GuruFocus requires market premium to be 6%.
Cost of Equity = 4.616% + 7.2706 * 6% = 48.2396%
3. Cost of Debt:
GuruFocus uses latest TTM Interest Expense divided by the latest one-year semi-annual average debt to get the simplified cost of debt.
As of Sep. 2025, Jin Medical International's interest expense (positive number) was $-0 Mil. Its total Book Value of Debt (D) is $15.4767 Mil.
Cost of Debt = -0 / 15.4767 = 0%.
4. Multiply by one minus TTM Tax Rate:
GuruFocus uses the most recent TTM Tax Expense divided by the most recent TTM Pre-Tax Income to calculate the tax rate. The calculated TTM tax rate is limited to between 0% and 100%. If the calculated tax rate is higher than 100%, it is set to 100%. If the calculated tax rate is less than 0%, it is set to 0%.
The latest calculated TTM Tax Rate = 0.215 / 1.596 = 13.47%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jin Medical International (ZJYL) has a WACC % of 24.01% as of Jul. 15, 2026. The weighted average cost of capital (WACC) is the average rate a company pays to finance assets. View historical data on Jin Medical International and its competitors. This is 163% above median its historical median of 9.13. Over the past decade, Jin Medical International's WACC % has ranged from 0.31 to 24.01. According to the industry distribution chart, Jin Medical International ranks #851 out of 865 companies in the Medical Devices & Instruments industry, placing it in the top 98.4%.
Is Jin Medical International's WACC % too high?
Jin Medical International's current WACC % of 24.01% is 163% above median its 10-year median of 9.13. Over the past 10 years, this metric has ranged from a low of 0.31 to a high of 24.01. The Medical Devices & Instruments industry median WACC % is 9.15. Jin Medical International's value of 24.01% is 162.4% above this industry median. Based on the distribution chart, Jin Medical International ranks #851 out of 865 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Jin Medical International has a GF Score™ of 64/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Jin Medical International's WACC % compare to RVP and CUPR?
According to the Medical Devices & Instruments industry distribution chart, Jin Medical International ranks #851 out of 865 companies for WACC %. This places Jin Medical International in the lower half of its industry. The industry median WACC % is 9.15. Jin Medical International's value of 24.01% is 162.4% above this benchmark. Historically, Jin Medical International's own WACC % has ranged from 0.31 to 24.01 over the past decade. While the company's 10-year median is 9.13 vs. the industry median of 9.15, Jin Medical International has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good WACC % for a Medical Devices & Instruments company?
The median WACC % among Medical Devices & Instruments companies is 9.15, based on 865 companies in the industry. Companies in the top quartile (top 25%) have a WACC % significantly above this median, while those in the bottom quartile fall well below. However, WACC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Jin Medical International's current WACC % of 24.01% is 162.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high WACC % mean?
A high WACC % can signal that a stock is expensive relative to its fundamentals. The weighted average cost of capital (WACC) is the average rate a company pays to finance assets. View historical data on Jin Medical International and its competitors. For the Medical Devices & Instruments industry, the median WACC % is 9.15 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jin Medical International's current WACC % is 24.01%, which is 163% above median its own 10-year median of 9.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jin Medical International stock overvalued right now?
Based on GuruFocus' analysis, Jin Medical International (ZJYL) is currently considered Significantly Undervalued. The stock's GF Value™ is $14.58, compared to a current price of $1.96 — trading 86.6% below its estimated fair value. The current WACC % is 24.01%, which is 163% above median its 10-year median of 9.13 and 162.4% above the Medical Devices & Instruments industry median of 9.15. Jin Medical International's overall GF Score™ is 64/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is WACC % calculated?
WACC % is calculated from a company's financial statements. For Jin Medical International (ZJYL), the current WACC % is 24.01% as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Jin Medical International (ZJYL) Overvalued in 2026?
Based on GuruFocus' analysis, Jin Medical International stock appears to be undervalued.
The current stock price of $1.96 is trading 86.6% below its estimated GF Value™ of $14.58.
GuruFocus considers Jin Medical International to be Significantly Undervalued.
Key valuation signals for ZJYL:
WACC %: 24.01% (163% above median its 10-year median of 9.13)
GF Value™: $14.58 vs. price of $1.96 (86.6% below fair value)
Industry Position: 162.4% above the Medical Devices & Instruments median (#851 of 865)
No single metric tells the full story. See the ZJYL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Jin Medical International Ltd, along with its subsidiaries, mainly offers rehabilitation equipment. It is engaged in the design, development, manufacturing, and sales of wheelchairs and other assistive living aid products for use by people with disabilities or impaired mobility. The group's product offering includes wheelchairs and wheelchair components, oxygen concentrators, bathing machines, respiratory and walking aids, oxygen chambers, beauty instruments, and nano products, among others. Wheelchairs are currently its key revenue-generating product. The products are sold to dealers in Japan and China, and to some extent to dealers located in the United States, Canada, Australia, Korea, Israel, Singapore, and other regions. Geographically, the group generates maximum revenue from Japan.
64GF Score
Get the complete analysis for ZJYL
WACC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ZJYL has been successfully added to your 
